Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon

<p>In December 2022, Atara Biotherapeutics’ Ebvallo received European Commission approval as the first-ever therapy for adults and children with EBV+ PTLD. The ground-breaking approval represents the first approval of an allogeneic T-cell immunotherapy ever, globally. Atara Bio&apos;s CEO, Pascal Touchon, talks to Cell &amp; Gene: The Podcast&apos;s Erin Harris about the biopharma&apos;s path to regulatory approval, commercialization plans for Ebvallo, an in-depth look at EBV+ PTLD, the connection between EBV and serious diseases like multiple sclerosis (MS), and much more.</p>